Arbutus to present AB-729 and AB-836 data at EASL Congress 2023

Arbutus Biopharma Corp

AB-729 + IFN in virally suppressed chronic HBV: well tolerated, mean HBsAg decline >1.6 log10 after 24 weeks.
88% of subjects achieved HBsAg <100 IU/mL; 2 subjects reached HBsAg <LLOQ during IFN treatment.
AB-836 capsid inhibitor: no viral breakthrough or enrichment of resistant variants after 28 days across 48 subjects.
Multiple core protein variants observed at higher frequencies, suggesting viral plasticity at those sites.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.